(lp0
S'Neurocrine Biosciences Inc Risk Points versus Health Care CML News - 10 hours ago This is a scatter plot analysis of the critical risk points from the option market for Neurocrine Biosciences Inc  compared to its own past and the Health Care ETF.'
p1
aS"Revenue Approximations Analysis: Neurocrine Biosciences, Inc. (NBIX ... StockNewsJournal - 17 hours ago Investors who are keeping close eye on the stock of Neurocrine Biosciences, Inc.  established that the company was able to keep return on investment at -36.00 in the trailing twelve month while Reuters data showed that industry's average&nbsp;...Neurocrine Biosciences, Inc. , Convergys Corporation  Stock Eyes ... - The USA Commerce"
p2
aS'Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros MD ... PR Newswire  - Jan 6, 2017 SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. , a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre &quot;DA&quot; Gros M.D.Neurocrine Biosciences  Gains as FDA Cancels INGREZZA AdCom; PDUFA Date ... - StreetInsider.comWhat Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NASDAQ ... - Market Exclusive'
p3
aS'Market Focus: Zooming in on Shares of Neurocrine Biosciences, Inc.  Rives Journal - 8 hours ago Tracking shares of Neurocrine Biosciences, Inc. , the company has a current EV  of 3389152.'
p4
aS"NEUROCRINE BIOSCIENCES, INC.  Files An 8-K Other Events Market Exclusive - Mar 13, 2017 On March 13, 2017, Neurocrine Biosciences, Inc.  announced it had completed the screening process and initiated hiring the Company's field-based sales representatives of approximately 140 professionals.Summary of Stock Move: Neurocrine Biosciences, Inc.  - Is storiesThe Asset Management One Co. Ltd. Cuts Stake in Neurocrine Biosciences, Inc ... - Petro Global News 24"
p5
aS'Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin ... PR Newswire  - Dec 21, 2016 SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. , a biotechnology company focused on neurological and endocrine related disorders, announced today that Timothy P. Coughlin will be stepping down from his&nbsp;...'
p6
aS'About: Neurocrine Biosciences,  Seeking Alpha - Feb 16, 2017 Neurocrine is heading toward multiple major milestones in 2017, including potential approval of its first drug, an NDA filling for another, and an important gating Phase II study.'
p7
aS'The Positive Investment Case For Neurocrine Biosciences Seeking Alpha - Feb 3, 2017 Founded in 1996, Neurocrine Biosciences is a San Diego, CA,-based biopharmaceutical concern with two late-stage clinical programs that are focused on neurological and endocrine based diseases and disorders.How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke ... - PR Newswire '
p8
aS'Has Neurocrine Biosciences Hit A Jackpot With Ingrezza? Seeking Alpha - Dec 5, 2016 Today, Neurocrine Biosciences  is at the cusp of a major transformation, from being an R&amp;D focused company to a commercial organization.'
p9
aS"Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA ... PR Newswire  - Aug 31, 2016 SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc.  today announced that the U.S. Food and Drug Administration  has conditionally accepted the proprietary name &quot;INGREZZA&quot; for the Company's once-daily&nbsp;...Neurocrine Biosciences  Announces Submission of Valbenazine NDA as ... - StreetInsider.com"
p10
a.